Evidence map›Paper›PMID 26341740›Full record

Trial reportHaematologica2015

Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival.

Henk M Lokhorst, Bronno van der Holt, Jan J Cornelissen, Marie José Kersten, Marinus van Oers, Reinier Raymakers, Monique C Minnema, Sonja Zweegman, Gerard Bos, Nicolaas Schaap and 4 more

Abstract readClinical TrialComparative StudyLetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Immunotherapy in myeloma: how far have we come?Therapeutic advances in hematology · 2019
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Henk M LokhorstDepartment of Hematology, VU University Medical Center Amsterdam, The Netherlands h.lokhorst@vumc.nl.
Bronno van der HoltHOVON Data Center, Erasmus MC Cancer Center - Clinical Trial Center, Rotterdam, The Netherlands.
Jan J CornelissenDepartment of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands.
Marie José KerstenDepartment of Hematology, Academic Medical Center, Amsterdam, The Netherlands.
Marinus van OersDepartment of Hematology, Academic Medical Center, Amsterdam, The Netherlands.
Reinier RaymakersDepartment of Hematology, University Medical Center Utrecht, The Netherlands.
Monique C MinnemaDepartment of Hematology, University Medical Center Utrecht, The Netherlands.
Sonja ZweegmanDepartment of Hematology, VU University Medical Center Amsterdam, The Netherlands.
Gerard BosDepartment of Hematology, Academic Hospital Maastricht, The Netherlands.
Nicolaas SchaapRadboud University Nijmegen Hospital, Nijmegen, The Netherlands.
Shulamiet WittebolMeander Medical Center, Amersfoort, The Netherlands.
Okke de WeerdtAntonius Hospital, Nieuwegein, The Netherlands.
Rianne AmmerlaanHOVON Data Center, Erasmus MC Cancer Center - Clinical Trial Center, Rotterdam, The Netherlands.
Pieter SonneveldDepartment of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Stem Cell TransplantationAllograftsAutograftsDisease-Free SurvivalFemaleHumansMaleMultiple MyelomaSurvival Rateallogeneic stem cell transplantationmyelomaprognosis

Identifiers

PMID26341740
PMCPMC4666343

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.